THE Pharmaceutical Benefits Advisory Committee (PBAC) has recommended a post market review of etanercept biologic alternatives for treatment of severe chronic plaque psoriasis.
Medicines included in the review are adalimumab, etanercept, infliximab, ustekinumab, secukinumab and ixekizumab.
A Stakeholder Forum will be held in Melbourne on 20 Oct 2017 to allow for further input.
CLICK HERE for an invitation.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jul 17
